Holen Sie sich die Stockscreener-App
14.04
5.33%
0.71
Handel nachbörslich:
13.82
-0.22
-1.57%
Schlusskurs vom Vortag:
$13.33
Offen:
$13.29
24-Stunden-Volumen:
1.43M
Relative Volume:
1.07
Marktkapitalisierung:
$1.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.76M
KGV:
-43.77
EPS:
-0.3208
Netto-Cashflow:
$-42.09M
1W Leistung:
+7.18%
1M Leistung:
+27.52%
6M Leistung:
+37.78%
1J Leistung:
+135.97%
1-Tages-Spanne:
$13.22
$14.09
1-Wochen-Bereich:
$12.74
$14.09
52-Wochen-Spanne:
$5.3801
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.04 | 1.69B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Inflation Data: Is Trevi Therapeutics Inc a top pick in the sectorChart Signals & Safe Entry Trade Reports - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN
Trevi Therapeutics (TRVI) asks shareholders to approve stock-plan refresh and share increase - Stock Titan
Stock Market Recap: Can Trevi Therapeutics Inc continue delivering strong returns - baoquankhu1.vn
Trevi Therapeutics, Inc. (TRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2%Here's What Happened - MarketBeat
Trevi Therapeutics, Inc. (TRVI) stock price, news, quote and history - Yahoo Finance Singapore
A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough - Yahoo Finance
Trevi Therapeutics (TRVI) Encounters Execution Uncertainty as Investors Anticipate Insights from May 7 Investor Day - Bitget
TRVI Technical Analysis & Stock Price Forecast - Intellectia AI
TRVI Forecast, Price Target & Analyst Ratings | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill
Trevi Therapeutics to Participate in Upcoming Events - Sahm
Trevi brings chronic cough specialists to New York investor day - Stock Titan
These analysts revise their forecasts on Trevi Therapeutics following Q4 earnings - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Vanguard (TRVI) amends 13G/A after Jan 12, 2026 realignment - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Shares Up 9.4%What's Next? - MarketBeat
Aug Wrap: Will Trevi Therapeutics Inc outperform tech stocks2026 Trading Recap & AI Powered Trade Plan Recommendations - baoquankhu1.vn
TRVI SEC FilingsTrevi Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
TRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trevi Therapeutics edges higher amid takeover speculation - MSN
Research Analysts Issue Forecasts for TRVI FY2026 Earnings - MarketBeat
Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus
Trading Action: Can Trevi Therapeutics Inc continue delivering strong returnsMarket Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings - Sahm
TRVI: Jones Trading Lowers Price Target While Maintaining Buy Ra - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
What is HC Wainwright's Forecast for TRVI Q1 Earnings? - MarketBeat
Does Trevi Therapeutics (TRVI) have the potential to rally 102.07% as Wall Street analysts expect? - MSN
Trevi Therapeutics Q4 Earnings Call Highlights - MarketBeat
Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected - news.alphastreet.com
Morgan Stanley Lowers Price Target for Trevi Therapeutics (TRVI) to $18.00 | TRVI Stock News - gurufocus.com
Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley - MarketBeat
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating By Investing.com - Investing.com India
Trevi Therapeutics Chronic Cough Programs: FDA End-of-Phase 2 Meeting & Phase III PlansNews and Statistics - IndexBox
Trevi Therapeutics 2025 Annual Report Highlights: Haduvio Development, Clinical Progress, and Competitive Position - Minichart
Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved - MSN
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Trevi Therapeutics (TRVI) Earnings Transcript - AOL.com
TRVI: Today's Analyst Rating Maintained at Buy with $19 Target | - GuruFocus
Needham raises Trevi Therapeutics stock price target on trial plans By Investing.com - Investing.com Canada
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):